FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

K Nishikawa

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Physiology

Platelet Aggregation

Anatomy

Vascular Smooth Muscle

Co-author Network

Publications

TOP 3
M Noda; Takanori Matsuo; R Fukuda; Masayuki Ohta; H Nagano; Yumiko Shibouta; T Naka; K Nishikawa; Yoshimi Imura
Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
T Naka; K Kubo; Y Inada; K Nishikawa
A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
Y Inada; M Ojima; R Kanagawa; Y Misumi; K Nishikawa; T Naka
Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of K Nishikawa (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

1999: M Noda; Takanori Matsuo; R Fukuda; Masayuki Ohta; H Nagano; Yumiko Shibouta; T Naka; K Nishikawa; Yoshimi Imura
Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
Kidney international 1999;56(3):898-909.
1999: T Naka; K Kubo; Y Inada; K Nishikawa
A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
Drug design and discovery 1999;16(2):95-108.
1999: Y Inada; M Ojima; R Kanagawa; Y Misumi; K Nishikawa; T Naka
Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Journal of human hypertension 1999;13 Suppl 1():S75-80.
1998: K Nishikawa
Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
Journal of human hypertension 1998;12(5):301-9.
1997: M Noda; R Fukuda; Takanori Matsuo; Masayuki Ohta; H Nagano; Yoshimi Imura; K Nishikawa; Yumiko Shibouta
Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Kidney international. Supplement 1997;63():S136-9.
1997: Y Inada; T Wada; M Ojima; T Sanada; Yumiko Shibouta; R Kanagawa; Y Ishimura; Y Fujisawa; K Nishikawa
Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1997;19(7):1079-99.
1997: K Nishikawa; T Naka; F Chatani; Y Yoshimura
Candesartan cilexetil: a review of its preclinical pharmacology.
Journal of human hypertension 1997;11 Suppl 2():S9-17.
1997: M Ojima; Y Inada; Yumiko Shibouta; T Wada; T Sanada; K Kubo; K Nishikawa
Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
European journal of pharmacology 1997;319(1):137-46.
1996: T Wada; T Sanada; M Ojima; R Kanagawa; K Nishikawa; Y Inada
Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats.
Hypertension research : official journal of the Japanese Society of Hypertension 1996;19(4):247-54.
1996: T Wada; Y Inada; M Ojima; T Sanada; Yumiko Shibouta; K Nishikawa
Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Hypertension research : official journal of the Japanese Society of Hypertension 1996;19(2):75-81.
1996: Yumiko Shibouta; F Chatani; Y Ishimura; T Sanada; M Ohta; Y Inada; K Nishikawa
TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats.
Kidney international. Supplement 1996;55():S115-8.
1995: Yoshimi Imura; Y Kiyota; Y Nagai; K Nishikawa; Z Terashita
Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
Thrombosis research 1995;79(1):95-107.
1995: Z Terashita; Yoshimi Imura; M Kawamura; K Kato; K Nishikawa
Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
Thrombosis research 1995;77(5):411-21.
1995: T Wada; R Kanagawa; Y Ishimura; Y Inada; K Nishikawa
Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Journal of hypertension 1995;13(1):113-22.
1994: Y Inada; T Wada; Yumiko Shibouta; K Nishikawa
[Nonpeptide angiotensin II-receptor antagonists].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 1994;104(3):217-28.
1994: M Kawamura; T Kitayoshi; Z Terashita; S Fujiwara; M Takatani; K Nishikawa
Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
Journal of lipid mediators and cell signalling 1994;9(3):255-65.
1994: H Fukushi; H Mabuchi; Z Terashita; K Nishikawa; H Sugihara
Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
Chemical & pharmaceutical bulletin 1994;42(3):551-9.
1994: T Wada; Y Inada; T Sanada; M Ojima; Yumiko Shibouta; M Noda; K Nishikawa
Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone.
European journal of pharmacology 1994;253(1-2):27-34.
1994: K Nishikawa; Y Inada; Yumiko Shibouta; T Wada; M Ojima; K Kubo; T Naka
Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Blood pressure. Supplement 1994;5():7-14.
1993: M Kawamura; Z Terashita; H Okuda; Yoshimi Imura; A Shino; M Nakao; K Nishikawa
TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.
The Journal of pharmacology and experimental therapeutics 1993;266(3):1664-9.
1993: K Kubo; Y Kohara; Y Yoshimura; Y Inada; Yumiko Shibouta; Y Furukawa; T Kato; K Nishikawa; T Naka
Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
Journal of medicinal chemistry 1993;36(16):2343-9.
1993: K Nishikawa
[Nonpeptide angiotensin II receptor antagonists].
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 1993;38(11):1873-80.
1993: K Kubo; Y Kohara; E Imamiya; Y Sugiura; Y Inada; Y Furukawa; K Nishikawa; T Naka
Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
Journal of medicinal chemistry 1993;36(15):2182-95.
1993: Yumiko Shibouta; Y Inada; M Ojima; T Wada; M Noda; T Sanada; K Kubo; Y Kohara; T Naka; K Nishikawa
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
The Journal of pharmacology and experimental therapeutics 1993;266(1):114-20.
1993: K Kubo; Y Inada; Y Kohara; Y Sugiura; M Ojima; K Itoh; Y Furukawa; K Nishikawa; T Naka
Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.
Journal of medicinal chemistry 1993;36(12):1772-84.
1993: M Kawamura; Z Terashita; Yoshimi Imura; A Shino; K Nishikawa
Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation.
Thrombosis research 1993;70(4):281-93.
1992: Z Terashita; M Takatani; K Nishikawa
Pharmacological profile of TCV-309--a potent PAF antagonist.
Journal of lipid mediators 1992;5(2):183-5.
1992: Z Terashita; M Kawamura; M Takatani; S Tsushima; Yoshimi Imura; K Nishikawa
Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
The Journal of pharmacology and experimental therapeutics 1992;260(2):748-55.
1991: M Takatani; N Maezaki; Yoshimi Imura; Z Terashita; K Nishikawa; S Tsushima
Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
Advances in prostaglandin, thromboxane, and leukotriene research 1991;21B():943-6.
1989: M Takatani; Y Yoshioka; A Tasaka; Z Terashita; Yoshimi Imura; K Nishikawa; S Tsushima
Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
Journal of medicinal chemistry 1989;32(1):56-64.
1988: Y Shibouta; T Kitayoshi; G Kitoh; K Nishikawa
Calcium channel blocking action of franidipine hydrochloride (CV-4093.2HCl) in vitro and in vivo.
Japanese journal of pharmacology 1988;48(4):463-72.
1988: Y Inada; M Tanabe; K Itoh; H Sugihara; K Nishikawa
Inhibition of angiotensin converting enzyme by (R)-3-[(S)-1-carboxy-5-(4-piperidyl)pentyl]amino-4-oxo-2,3,4,5-tetra- hydro-1,5-benzothiazepine-6-acetic acid (CV-5975), a non-sulfhydryl compound.
Japanese journal of pharmacology 1988;48(3):323-30.
1987: Z Terashita; Yoshimi Imura; A Shino; K Nishikawa
A lethal role of platelet activating factor in anaphylactic shock in mice.
The Journal of pharmacology and experimental therapeutics 1987;243(1):378-83.
1987: Z Terashita; Yoshimi Imura; M Takatani; S Tsushima; K Nishikawa
CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
The Journal of pharmacology and experimental therapeutics 1987;242(1):263-8.
1983: Z Terashita; S Tsushima; Y Yoshioka; H Nomura; Y Inada; K Nishikawa
CV-3988 - a specific antagonist of platelet activating factor (PAF).
Life sciences 1983;32(17):1975-82.